Feasibility and Safety of Allogeneic Adipose Mesenchymal Stem Cells (aMSCs) Delivery Into Kidney Allografts Procured From Deceased Donors With High Kidney Donor Profile Index (KDPI)

• Status: Recruiting
• Trial end date: 2024-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to test an investigational drug called Adipose Mesenchymal Stem Cells (aMSCs) for the treatment of ischemia re-perfusion injury (IRI) in patients that have had a kidney transplant.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tambi Jarmi

Criteria

Inclusion Criteria:

• Male or female kidney transplant candidates age 18 and above.

• Patient is receiving kidney allograft from deceased donor with KDPI>85%.

• Ability of subject to give appropriate consent.

• Females of childbearing potential with agreement to use birth control for six months post-transplant.

• Approved by the Mayo Clinic Transplant Selection Committee.

• Signed Authorization for Donation of Anatomical Gifts on file.

Exclusion Criteria:

• Positive pregnancy test at the time of the kidney offer is called for the potential recipient.

• Kidney transplant potential recipients with active malignancy (except none melanoma skin malignancies).

• Patients with previous history of solid organ transplant (Heart, Lung, Intestine, Kidney and/or Pancreas).

• Patients with previous history of bone marrow transplant.